A
Alcista
Alcista · 25%BTAI
$0.94
Precio del escenario
$0.074
-0.027 (-37.11%)Al cierre
Loading chart…
- Máximo
- 0.094
- Apertura
- 0.093
- Precio medio ponderado por volumen
- 0.08
- Volumen
- 47.48M
- Capitalización
- 47.66M
- Mínimo
- 0.069
- Importe
- 3.74M
- EV/EBITDA, TTM
- -0.08
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Análisis de IA of BioXcel Therapeutics Inc (BTAI)
VenderBioXcel Therapeutics Inc is not a good buy right now due to its significant financial distress and recent bankruptcy filing. The current price is $0.0739, which reflects a staggering 95.65% decline year-to-date. Additionally, the company has reported a gross margin of only 87.91% in the most recent quarter, indicating severe operational challenges. The primary risk is its recent bankruptcy filing, which raises concerns about the company's ability to continue operations and meet obligations.
Recomendaciones de analistas (4)
+7342.49% de potencial alcista
Comprar
4 Comprar
0 Mantener
0 Vender
Actual: 0.07
Mínimo
1.00
Promedio
5.50
Máximo
10.00
H.C. Wainwright
Comprar
$5
2026-04-02
H.C. Wainwright
2026-04-02
Precio objetivo
$5
Comprar
Rodman & Renshaw
Comprar
$17
2026-03-17
Rodman & Renshaw
2026-03-17
Precio objetivo
$17
Comprar
H.C. Wainwright
Comprar
$6
2026-03-05
H.C. Wainwright
2026-03-05
Precio objetivo
$6
Comprar
Mizuho
Neutral
$4
2025-09-12
Mizuho
2025-09-12
Precio objetivo
$4
Neutral
H.C. Wainwright
Comprar
$10
2025-08-15
H.C. Wainwright
2025-08-15
Precio objetivo
$10
Comprar
Métricas de valoración
El PER previsto actual de BioXcel Therapeutics Inc (BTAI) es 0.00, frente a su media de 5 años de -1.74.
Escenarios de precio de Alphio AI para BTAI
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BTAI en cartera
Cronología de eventos
Noticias
2.009-12Yahoo FinanceTeva Agrees to $125 Million Acquisition of BioXcel Assets
9.008-31NASDAQ.COMBioXcel Therapeutics Signs Asset Sale Agreement with Teva Pharmaceuticals
9.008-28NASDAQ.COMBioXcel Therapeutics Sells Assets and Files for Bankruptcy
9.008-28NewsfilterBioXcel Therapeutics Initiates Asset Sale Process Under Bankruptcy
8.508-13CNBCGIFT City in India Attracts Global Asset Management Firms
Preguntas frecuentes sobre BTAI, respondidas por Alphio AI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
BioXcel Therapeutics Inc is not a good buy right now due to its significant financial distress and recent bankruptcy filing. The current price is $0.0739, which reflects a staggering 95.65% decline year-to-date. Additionally, the company has reported a gross margin of only 87.91% in the most recent quarter, indicating severe operational challenges. The primary risk is its recent bankruptcy filing, which raises concerns about the company's ability to continue operations and meet obligations.
4 analysts cover BTAI: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Equal-Weight vs Cap-Weighted S&P 500: RSP vs SPY After October's Rotation and Nvidia's CEO ShockEqual weight vs cap weighted S&P 500: how RSP and SPY differ, why October 2026's rotation was the widest since 2009, and how to blend both after Nvidia's shock.
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.